MARKET

DRNA

DRNA

Dicerna
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.89
-0.50
-1.97%
After Hours: 24.89 0 0.00% 16:59 07/10 EDT
OPEN
25.53
PREV CLOSE
25.39
HIGH
25.79
LOW
24.82
VOLUME
310.87K
TURNOVER
--
52 WEEK HIGH
27.68
52 WEEK LOW
11.75
MARKET CAP
1.84B
P/E (TTM)
-14.7741
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average DRNA stock price target is 33.78 with a high estimate of 45.00 and a low estimate of 25.00.

EPS

DRNA News

More
Missed the biotech breakout? These stocks in the industry are still set to run, MKM says
Biotechnology stocks have ripped higher in 2020 and some investors might have missed their chance to capitalize on the surge.
CNBC.com · 07/03 12:37
Four biotech names heading for key Q3 catalysts
Seeking Alpha - Article · 07/02 03:58
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among 15 employees.
Business Wire · 07/01 20:30
Dicerna Receives Rare Pediatric Disease Designation From U.S. Food and Drug Administration for Nedosiran for Treatment of Primary Hyperoxaluria
Business Wire · 06/18 12:30
Dicerna nabs Rare Pediatric Disease tag for nedosiran for primary hyperoxaluria
Seeking Alpha - Article · 06/18 12:08
Dicerna Reports Rare Pediatric Disease Designation From FDA For Nedosiran For Treatment Of Primary Hyperoxaluria
Benzinga · 06/18 11:31
Hedge Funds Arent Crazy About Dicerna Pharmaceuticals Inc (DRNA) Anymore
Insider Monkey · 06/15 13:49
2 Top Small-Cap Stocks to Buy Right Now
Motley Fool · 06/12 13:31

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About DRNA

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It is focused on development of RNAi-based therapeutics using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases and cardiovascular diseases. Its development programs include dacryocystorhinostomy (DCR)-PHXC for the treatment of primary hyperoxaluria (PH), which is in a Phase I clinical trial; DCR-HBVS for the treatment of chronic hepatitis B virus (HBV), which is in a Phase I clinical trial, and a product candidate against a rare liver disease. It also developed a wholly owned clinical candidate, DCR-BCAT, targeting the β-catenin oncogene. DCR-BCAT is delivered by its lipid nanoparticle (LNP) tumor delivery system, EnCore.
More

Webull offers kinds of Dicerna Pharmaceuticals Inc stock information, including NASDAQ:DRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DRNA stock methods without spending real money on the virtual paper trading platform.